Data from: Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Cite this dataset
Formisano, Luigi et al. (2019). Data from: Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer [Dataset]. Dryad. https://doi.org/10.5061/dryad.20j465p
Abstract
Usage notes
Funding
National Science Foundation, Award: This study was supported by NIH Breast SPORE grant P50 CA098131, Vanderbilt-Ingram Cancer Center Support grant P30 CA68485, Susan G. Komen for the Cure Breast Cancer Foundation grant SAC100013, and a grant from the Breast Cancer Research Foundation. L.F. was supported by Italian Association of Medical Oncology. V.M. Jansen was supported by Conquer Cancer Foundation ASCO Young Investigator Award 8364, Susan G. Komen Postdoctoral Fellowship Grant PDF15329319 and the Vanderbilt Clinical Oncology Research Career Development Program (2K12CA090625-17). J.A. Bauer was supported by NCI Research Specialist Award R50 CA211206